Our findings provide evidence that NACT is likely to downstage tumors, allowing for BCS with lower ER and PR expression or higher Ki-67 expression and increasing the likelihood of BCS in early-stage, HR-positive/HER2-negative breast cancer that may otherwise require a mastectomy. This evidence concerns the gene ERBB2 and breast carcinoma.